Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis
Days ago Novartis posted a brief note on positive 16-week data about Cosentyx’s effects on non-radiographic axial spondyloarthritis, opening the door to an EMA submission in the indication. Now the pharma giant says it has the 52-week win needed to take to FDA regulators, too.
The new update puts Novartis’ blockbuster IL-17A drug on par with Eli Lilly’s rival therapy, Taltz, for which similar results were reported in April. Both drugs are already approved for another type of spondyloarthritis, but this particular form of inflammatory arthritis does not show visible evidence of damage on X-rays.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.